MUCINOUS ADENOCARCINOMA
Clinical trials for MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a chemo-immunotherapy combo tame hard-to-treat colorectal cancer?
Disease control OngoingThis study tests whether a short course of chemotherapy can make a type of advanced colorectal cancer (pMMR/MSS) more responsive to immunotherapy. The goal is to achieve long-term disease control or even eliminate tumors. About 80 adults with untreated, spread colorectal cancer w…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for recurrent ovarian cancer: drug combo extends life?
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…
Matched conditions: MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC